The definition of what constitutes a nano-cap varies with some saying the definition applies to companies whose stock valuation is less than $50 million.
Here is a roundup of several nano-cap pharmaceutical companies valued at around $50 million or less that are making headlines on Tuesday.
Of note to investors, pharmaceutical stocks of all sizes are subject to large swings and can result in large losses. As a perfect example, Bristol-Myers Squibb (NYSE: BMY) is a large mega-cap biopharmaceutical company and its stock has seen heavy losses after a cancer drug failed to live up to its expectations.
Prana Biotechnology Presents New Data
Prana Biotechnology (NASDAQ: PRAN), a medical biotechnology company that focuses on the treatment of Alzheimer’s disease and other age-related degenerative disorders, presented on Tuesday results from an ongoing clinical trial to treat Huntington Disease.
The company said that patients involved in its study showed a decrease in “memory complaints” after 26 weeks when they were treated with the company’s PBT2 250mg therapy versus a placebo.
Cesca Therapeutics Granted A Third Patent
Cesca Therapeutics (NASDAQ: KOOL), an autologous cell-based regenerative medicine company, announced on Tuesday that the U.S. Patent and Trademark Office (USPTO) granted the company its third family of patent applications related to its methods for the treatment of ischemic cardiovascular disorders.
The patent protects Cesca’s technology platform and delivery method.
KemPharm Announces Licensing Agreement
KamPharm (NASDAQ: KMPH), a clinical-stage specialty pharmaceutical company that focuses on proprietary prodrugs, announced on Tuesday it reached an agreement with Acura Pharmaceuticals (NASDAQ: ACUR).
As part of the agreement, Acura will provide KamPharm with its Aversion Technology for use in the development of its immediate release (IR) opioid product candidates.
Catalyst Biosciences Sells Asset
Catalyst Biosciences (NASDAQ: CBIO), a clinical-stage biopharmaceutical company that develops medicines to treat hematology indications, announced on Tuesday it has entered into an agreement sell an asset which was under development by Targecpt prior to its merger with Catalyst in 2015.
As part of the agreement, Catalyst Biosciences will sell one of its neuronal nicotinic receptor for an upfront payment of $750,000 and up to $37 million in development, regulatory and commercial milestone payments and royalties on net sales.
Catalyst Biosciences sold its asset so it can better focus on its core focus of hemostasis.